Volume 21, Issue 2 - Medical Writing in Paediatrics

Medicines information for patients: Insights into research and practice for medical writers

Author: DK Theo Raynor

Abstract

Download the full article

References

1. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;(2):CD000011.
2. Raynor DK, Blenkinsopp A, Knapp P, Grime J, Nicolson DJ, Pollock K, et al. A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. Health Technol Assess 2007;11:1–160.
3. Liberating the NHS: Greater choice and control. A consultation on proposals. London: Department of Health; 2010.
4. Directive 93/27 European Commission. Council Directive. The labelling of medicinal products for human use and on package leaflets. Brussels: European Commission; 1992.
5. Directive 2001/83 European Commission. Council Directive. Community code relating to medicinal products for human use. Brussels: European Commission; 2001.
6. European Commission. Guidance concerning consultations with target patient groups for the package leaflet. Brussels: European Commission; 2006
7. Sless D, Shrensky R. Writing about medicines for people. 3rd ed. Sydney: Australian Self-Medication Industry; 2006.
8. RPS. From compliance to conconcordance. London: Royal Pharmaceutical Society; 1997.
9. NICE. Clinical guideline CG76: Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. London: National Institute for Health and Clinical Excellence; 2009.
10. Raynor DK, Savage I, Knapp P, Henley J. We are the experts: people with asthma talk about their medicine information needs. Patient Educ Couns 2004;53:167–74.
11. Raynor DK, Dickinson D. Key principles to guide development of consumer medicines information. Ann Pharmacother 2009;43:700–6.
12. Berry DC, Knapp PR, Raynor D. Provision of information about drug side-effects to patients. Lancet 2002;359:853–4.
13. Knapp P, Gardner PH, Raynor DK, Woolf E, McMillan B. Perceived risk of tamoxifen side effects: a study of the use of absolute frequencies or frequency bands, with or without verbal descriptors. Patient Educ Couns 2010;79:267–71.
14. European Commission. Guidance concerning consultations with target patient groups for the package leaflet. Brussels: European Commission; 2006.
15. Medicines and Healthcare Products Regulatory Agency. Always read the leaflet: getting the best information with every medicine. Report of the Committee on Safety of Medicines Working Group on Patient Information. London: The Stationery Office; 2005.
16. Amending Directive 2001/83/EC, as regards information to the general public on medicinal products subject to medical prescription and as regards pharmacovigilance. Brussels: European Commission; 2011.
17. Quality Review of Documents Group. Human product information template v8.00. London: European Medicines Agency; 2011.
18. Raynor DK, Knapp P, Silcock J, Parkinson B, Feeney K. “User-testing” as a method for testing the fitness-for-purpose of written medicine information. Patient Educ Couns 2011;83:404–10.
19. Knapp P, Raynor DK, Silcock J, Parkinson B. Can user testing of a clinical trial patient information sheet make it fit-for-purpose? – a randomized controlled trial. BMC Med 2011;9: Article number 89.
20. Directive 2010/84 European Commission. Pharmacovigilance directive. Brussels: European Commission; 2010.